RARECast

A podcast by RARECast - Thursdays

Thursdays

Categories:

512 Episodes

  1. The Decision to Get Tested for Huntington's Disease and How It Changed Seth Rotberg's Life

    Published: 4/4/2018
  2. Nonprofit Sees Need in Developing Gene Therapies for Inherited Eye Disesases

    Published: 3/29/2018
  3. Casting a Wider Net for Genetic Diseases

    Published: 3/21/2018
  4. Corbus Seeks to Quiet the Immune System in Chronic Conditions

    Published: 3/14/2018
  5. Addressing the Challenges of Rare Disease Drug Development

    Published: 3/7/2018
  6. Giving Voice to Patients at the FDA

    Published: 2/28/2018
  7. Finding a Rare Friend

    Published: 2/21/2018
  8. Why a Sports Physical May Trigger a Doctor to Think About a Rare Diagnosis

    Published: 2/14/2018
  9. UPenn's Orphan Disease Center Takes a Rare Approach

    Published: 2/7/2018
  10. How Patients Can Accelerate Translational Research in Rare Disease

    Published: 1/31/2018
  11. Notre Dame Center Leverages Commonalities of Rare and Neglected Diseases

    Published: 1/24/2018
  12. GalXC Quest: Dicerna Bets on Its Unqiue Approach to RNAi

    Published: 1/17/2018
  13. Pharnext Takes a Unique Twist on Repurposing Drugs for Rare Diseases

    Published: 1/10/2018
  14. uniQure Seeks to Find Elusive Market Success with Hemophilia B Gene Therapy

    Published: 1/3/2018
  15. Savara Advances Pipeline of Inhaled Therapeutics for Rare Lung Diseases

    Published: 12/27/2017
  16. Why the Microbiome May Provide a Novel Approach to Treating Certain Rare Diseases

    Published: 12/20/2017
  17. FDA Outlines a Collaborative Approach for Pediatric Rare Disease Trials

    Published: 12/13/2017
  18. Why Patient-Centred Outcomes Are Critical to Rare Disease Drug Trials

    Published: 12/6/2017
  19. What the FDA's New Framework Means for Regenerative Therapies

    Published: 11/29/2017
  20. Measuring the Value of Therapies for Ultra-Rare Diseases

    Published: 11/22/2017

18 / 26

RARECast is a Global Genes podcast hosted by award-winning journalist Daniel Levine. It focuses on the intersection of rare disease with business, science, and policy.